Monthly Archives: July 2020

SphingoTec to Present at the LifeSci Partners’ Summer Symposium

Hennigsdorf/Berlin, Germany – July 31, 2020 – Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand von Humboldt, CFO, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. SphingoTec develops and markets in-vitro diagnostic tests…
Read more

sphingotec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

Endothelial dysfunction is driving pathophysiological processes such as congestion in heart failure, shock in sepsis, and lung dysfunction in COVID-19 Bioactive Adrenomedullin (bio-ADM®) is a proprietary biomarker for real-time assessment of endothelial function in acute and critical care settings. High blood levels of bio-ADM® have been shown to predict septic shock, to diagnose residual congestion…
Read more